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Thoracic aortic aneurysm and dissection (TAAD) is an autosomal-dominant disorder with major life-threatening complications. The
disease displays great genetic heterogeneity with some forms allelic to Marfan and Loeys-Dietz syndrome, and an important number
of cases still remain unexplained at themolecular level. Throughwhole-exome sequencing of affectedmembers in a large TAAD-affected
family, we identified the c.472C>T (p.Arg158*) nonsense mutation in MFAP5 encoding the extracellular matrix component MAGP-2.
This protein interacts with elastin fibers and the microfibrillar network. Mutation screening of 403 additional probands identified
an additional missense mutation ofMFAP5 (c.62G>T [p.Trp21Leu]) segregating with the disease in a second family. Functional analyses
performed on both affected individual’s cells and in vitro models showed that these two mutations caused pure or partial haploin-
sufficiency. Thus, alteration of MAGP-2, a component of microfibrils and elastic fibers, appears as an initiating mechanism of
inherited TAAD.Thoracic aortic aneurysms and dissection (TAAD) disorder
is a major cause of sudden death. TAAD is essentially a
multifactorial disease but 20% of cases are inherited in an
autosomal-dominantmanner andare found indistinct syn-
dromes or represent the only clinical feature of the disease.1
Researchof thepast 20yearshas shown that there is a strong
molecular overlap between these different clinical forms of
TAAD, mutations in the same genes being found to be
responsible for syndromic or isolated TAAD.2 The first syn-
drome to be associated with TAAD was Marfan syndrome
(MFS [MIM 154700/ORPHA558]). In the majority of cases,
MFS is due to mutations in FBN1 (MIM 134797) encoding
fibrillin-1, the major component of isolated microfibrillar
aggregates and themicrofibrillar componentof elastic fibers
in the extracellular matrix (ECM).3 In some cases, MFS
might also be due to mutations in TGFBR2 (MIM 190182),
thus demonstrating involvement of alterations in TGF-b
signaling as an initiating mechanism of TAAD.4 This was
further emphasized by the description of Loeys-Dietz
syndrome (LDS [MIM 609192/ORPHA60030]) with muta-
tions in TGFBR1 (MIM 190181)/TGFBR2 and the descrip-
tion of aneurysms-osteoarthritis syndrome (AOS [MIM
613795/ORPHA284984]) with mutations in SMAD3 (MIM
190220).5–7 Genetic mutations causing isolated TAAD
are found in all previous genes as well as TGFB2 (MIM1INSERM U1148, Laboratory for Vascular Translational Science, Hoˆpital Bichat
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smooth muscle cell (SMC) contractile apparatus: ACTA2
(MIM 102620), MYH11 (MIM 160745), MYLK (MIM
600922), and PRKG1 (MIM 176894).10–13 Although defects
in several genes lead to altered TGF-b signaling or SMC
contraction, defects in a single ECM protein (i.e., fribril-
lin-1) have been known until now to account for TAAD.
Finally, TAAD shows significant genetic heterogeneity but
80% remain unexplained at the molecular level.2
To identify additional mutations causing TAAD, we per-
formed whole-exome sequencing in TAAD-affected fam-
ilies in which no causal mutation had been identified in
genes previously associated with TAAD. Probands and fam-
ilies were recruited through the National Reference Center
for Marfan syndrome and related disorders and through
related centers nationwide. All affected individuals were
screened for diagnosis of possible syndromic (notably
MFS) or nonsyndromic TAAD through a multidisciplinary
clinic including systematic slit-lamp examination and
extensive imaging, aortic echography, and molecular anal-
ysis. Blood samples were obtained from affected individ-
uals in agreement with the French Bioethic laws (IRB:
CCP Ile de France XI, authorization #11 008; informed,
written consent was obtained) and genomic DNA prepared
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Figure 1. Pedigrees of Families TAA-9801 and TAA-9178
Black arrows indicate probands. DNA from circled individuals was used for whole-exome sequencing. Orange symbols indicate family
members heterozygous for mutations inMFAP5: c.472C>T (p.Arg158*) in TAA-9801 (A) and c.62G>T (p.Trp21Leu) in TAA-9178 (B). The
age at diagnosis is specified when available.Whole-exome sequencing was first performed with
DNA from four affected persons (circled individuals in
Figure 1A) from TAA-9801 (whole-exome sequencing
performed at Integragen S.A.). The female proband (II:14)
presented aortic root dilatation discovered during investi-
gation of lone paroxysmal atrial fibrillation at the age
of 50 years (aortic root diameter of 46 mm), which was
associated with mitral valve prolapse and slight skeletal
features (pectus excavatum and arachnodactyly). Family
history indicated that her 83-year-old mother (I:1) had a
history of atrial fibrillation and presented with Alzheimer
disease. Interestingly, a maternal aunt died suddenly at
62 years old and also had a history of atrial fibrillation.
Additionally, coronary artery bypass surgery was per-
formed in a maternal uncle at age 60 years, and there
was family history of stroke at 55 years, sudden death
before the age of 50 years, and heart disease at the age of
55 years reported in three brothers of the maternal grand-
mother. Clinical familial screening allowed recognition of
aortic dilatation (aortic root diameter of 43 mm) in the son
of the proband (III:11), without any extra-aortic features,
and a sister of the proband (II:10) presented aortic root
dilatation (46mm) and skeletal features (pectus carinatum,
arachnodactyly, highly arched palate). Of note, she also
suffered lone atrial fibrillation, as did her sister, and com-
plained of migraine; aortic dilatation (aortic root diameter
at 50 mm) was also observed in the brother of the proband
(II:15), with mild skeletal features (i.e., pectus excavatum).The AmericanThe aortic diameter was within normal limits (Z ¼ 1.8) in
his son (III:12) at the age of 16 (who also presented pectus
excavatum) and slightly enlarged (Z ¼ 2.3) in his second
son at age of 12 (III:13). Lastly, a nephew of the proband
(III:1) was screened at the age of 36 years and had an aortic
root diameter at the upper limit of normal values (38 mm).
Detailed clinical features are presented in Table S1 available
online.
DNAwas subjected to the exome-capture procedure with
the Agilent SureSelect Human All Exon kit (V4, 50 Mb)
according to the manufacturer’s protocols. Paired-end
sequencing was performed on an Illumina HiSeq 2000,
and the short reads (75 bp) were aligned to the Human
Genome (UCSC hg19) by CASAVA 1.8. Image analysis
and base calling were performed with Illumina Real Time
Analysis (RTA) Pipeline v.1.14 with default parameters.
The alignment algorithm used was ELANDv.2. Variation
annotation was performed with an in-house pipeline of
Integragen S.A. Sequencing results were filtered for a
depth R103 and for novel heterozygous variants shared
between these four affected relatives and absent from
dbSNP, 1000 Genomes, HapMap, Exome Variant Server,
and in-house whole-exome data set of 176 additional
exomes. Nonsense, missense, insertion/deletion, and
splice variants were carefully examined.
The filtering strategy identified 17 shared novel vari-
ants including 14 missense and 3 nonsense variants (Table
S3). Nonsense mutations were detected in FER1L5Journal of Human Genetics 95, 736–743, December 4, 2014 737
(c.4111C>T), GATA6 (MIM 601656) (c.457C>A), and
MFAP5 (MIM 601103) (c.472C>T). FER1L5 (encoding the
Fer-1-Like 5 [C. elegans gene]) is involved in myoblast
fusion. GATA6 encodes a zinc finger transcription factor
that plays an important role in cell differentiation and
organogenesis during vertebrate development. GATA6
haploinsufficiency has been reported as a frequent cause
of diabetes with pancreatic agenesis and congenital heart
defects.14,15 Pancreatic agenesis and gut and heart malfor-
mations in subjects heterozygous for the GATA6 variation
were checked and excluded after careful examination of
scanner imaging in TAA-9801 individuals, meaning that
haploinsufficiency for GATA6 does not lead systematically
to the described organogenesis defects. Bidirectional
Sanger DNA sequencing of GATA6mutation (RefSeq acces-
sion number NM_005257.5) was performed in other avail-
able DNA from members of TAA-9801. The segregation of
this variant in TAA-9801 did not corroborate with TAAD
(data not shown).
The third candidate, MFAP5 (Microfibrillar Associated
Protein 5), encodes MAGP-2 (Microfibril-Associated Glyco-
protein 2), a component of the ECM interacting with
fibrillin-1 and present in isolated or elastin-associated mi-
crofibrils.16 The nonsense MFAP5 mutation (RefSeq
NM_003480.3) was sequenced in TAA-9801. Good familial
segregation was observed (Figure 1A). Therefore, other
mutational events inMFAP5were looked for inapopulation
of 225 familial probands and178 simplexTAAD-affected in-
dividuals of French origin and 267 TAAD-affected individ-
uals from the Texas collection by systematic Sanger DNA
sequencing of all exons (sequencing primers listed in Table
S2). One additional MFAP5 variant (c.62G>T) was identi-
fied in the proband of TAA-9178 and two affected relatives
(Figure 1B). The female proband presented aortic dissection
typeAat the ageof 58yearswithno skeletal, ophthalmolog-
ical, cutaneous, or pulmonary features. Investigation of her
69-year-old sister (II:1) imaged thoracic aortic aneurysm
(aortic root diameter at 41mm) in the context of hyperten-
sion with left ventricular hypertrophy. She presented no
extra aortic features, but had ahistory of breast cancer, glau-
coma, and hypothyroidism. The proband’s 38-year-old
daughter (III:1) had an aortic root diameter at the upper
limit of normal values (35 mm), no skeletal features, and
no medical problem beyond migraines. Detailed clinical
features are presented in Table S1. The variation leads to a
substitution in theN-terminal domain ofMAGP-2 affecting
a very conserved tryptophan (p.Trp21Leu) (Figure 2). This
substitution is located close to the putative peptide-signal
cleavage site and predicted to be possibly damaging by
Polyphen-2 and MutationTaster and as pathogenic by
UMD-Predictor.17
The effect of mutations at the mRNA and protein levels
was investigated in subject dermal fibroblasts explanted
from three affected members from families TAA-9801
(II:10 and II:15) and TAA-9178 (II:2). Because the
c.472C>T variation was located in the last exon of
MFAP5, it was not expected to cause nonmediated decay738 The American Journal of Human Genetics 95, 736–743, Decemb(NMD). This was confirmed by the sequencing of the
MFAP5 transcript in fibroblasts from two family relatives
who both showed similar levels of mutant and wild-type
transcripts in fibroblasts grown with and without emetine
(Figure 2, sequencing primers listed in Table S2). Immu-
noblot analysis was performed with fibroblasts from
heterozygous persons with antibodies directed against
N-terminal (sc-134437 from Santa Cruz Biotechnology)
and C-terminal (ab47826 obtained from Abcam) parts of
MAGP-2. Results suggested that although the mutant tran-
script is expressed, the truncated protein present in cellular
lysates is probably degraded by an endoplasmic-reticulum-
associated degradation pathway because no extracellular
signal was detected for the truncated protein (Figures 3A
and 3B). This result showed that c.472C>T leads to pure
haploinsufficiency in heterozygous persons (Figure 3C).
Immunoblots on fibroblasts from heterozygous persons
with the c.62G>T mutation (TAA-9178) were also per-
formed. Presence of MAGP-2 at the expected molecular
weight was observed (Figures 3A and 3B). However, intra-
cellular levels of the protein appeared to be lower in
c.62G>T-carrying fibroblasts.
Site-directed mutagenesis and transfection assays were
performed to fully investigate specific effects of each
MFAP5 mutation identified as cells from heterozygous
subjects constitutively expressing both WT and mutated
alleles. The c.472C>T and c.62G>T MFAP5 mutations
were introduced separately in plasmids containing the
wild-type (WT) coding sequence of MFAP5 with the
QuikChange II Site-Directed Mutagenesis Kit, according
to manufacturer’s instruction (Agilent Technologies). The
coding sequence of MFAP5 is cloned into pCMV6-XL5
vector suitable for mammalian cell overexpression assays
(Origene Technologies). After selecting clones, plasmids
were purified with the Plasmid Maxi kit (QIAGEN). The
presence of the c.472C>T or the c.62G>T mutations and
the absence of other coding variations were checked
by bidirectional Sanger sequencing via primers spanning
the coding sequence of MFAP5 (available upon request).
Results confirmed that c.472C>T abrogates MAGP-2 pro-
duction (Figures 4A and 4B). Conversely, the signal from
p.Trp21Leu MAGP-2 was present but significantly lower
than that of WT MAGP-2 in cellular lysates (p ¼ 0.03) (Fig-
ures 4C and 4E). An important fraction of mutated pro-
teins might be recognized and degraded by the unfolded
protein response. The extracellular signal obtained with
both antibodies for WT and mutant MAGP-2 constructs
was consistently diffuse. However, careful observation of
immunoblots revealed for p.Trp21Leu MAGP-2 a shift
toward higher molecular weight bands (Figure 4D). So, it
is clear that p.Trp21Leu alters posttranslational modifica-
tions and/or extracellular processing of MAGP-2. Interest-
ingly, it has been shown that mouse MAGP-2 is subject
to a cleavage by proprotein convertases (PC) and that
alteration of this cleavage reduces matrix-associated
MAGP-2.18,19 Such proteolytic processing seems to have
a physiological importance as observed with other ECMer 4, 2014
Figure 2. Structure of MFAP5 and MAGP-2
MFAP5 consists of ten exons (squares) with nine coding exons (blue squares). Mutations detected in this study appear under the gene
schematic.MFAP5 encodes MAGP-2 for which the protein structure is depicted above the genomic structure. Scissors indicate the puta-
tive cleavage sites for the signal peptide (SP) peptidase and for proprotein convertases (RLRR). Putative site for cell attachment (RGD) and
N- and O-Glycosylations (N-Glyc and O-Glyc) are also indicated. The electrophoregrams of each mutation obtained from Sanger
sequencing appear below the genomic structure. The affected codons are underlined in black. Substitution c.62G>T (left) affects an
evolutionary conserved tryptophan among mouse, rat, dog, cat, and chicken. Multiple sequence alignment was performed with
CLUSTAL Omega. Comparative sequencing of mutation c.472C>T from genomic DNA and transcript of MFAP5 (cDNA) are presented
(right). cDNA from individual TAA-9801 II:15 was obtained from mRNA harvested from primary fibroblasts grown with or without
emetine to block the NMD RNA surveillance pathway.proteins including fibrillin-1.20,21 The cleavage site being
conserved in human (putative consensus site located be-
tween amino acids 152 and 153), p.Trp21Leu might alter
the recognition of the cleavage site by proprotein conver-
tases leading to an enrichment in full-length proteins
versus cleaved MAGP-2. Thus, alteration of this process
by p.Trp21Leu might affect interactions of MAGP-2 with
other ECM proteins or deposition in microfibrils.
In parallel, aortic tissue was collected at the time of
surgery from the TAA-9178 proband (II:2) (Bichat Univer-
sity Hospital). Histological analyses showed typical fea-
tures of TAAD: staining with Masson’s trichrome and
alcian blue revealed a disorganization of the media with
loss of SMCs and proteoglycan accumulation, respectively
(Figure 5A). In parallel, a possible effect of MFAP5 loss-of-
function mutations on the TGF-b signaling pathway was
investigated. Indeed, it is well established that the microfi-
brillar network acts as a reservoir for latent TGF-b. Assess-
ment of TGF-b1 and nuclear phosphorylated SMAD2/3
showed greatly enhanced TGF-b signaling in the aorta
from the individual with MFAP5 mutation (Figure 5B).The AmericanParadoxically, upregulation of TGF-b signaling is a major
hallmark of syndromic and isolated TAAD aneurysmal
aortas regardless of their etiologies.22 Thus, in reducing
the TGF-b1 reservoir in ECM, MFAP5 loss of function in-
duces upregulation of the TGF-b/BMP signaling pathway.
Finally, deleterious variations in MFAP2 (MIM 156790)
(paralog ofMFAP5 inmouse and also in human, and encod-
ing MAGP-1) were looked for in the collection of French
TAAD-affected individuals. All exons were systematically
screened andnovariation that could account for thedisease
was identified (sequencing primers listed in Table S2).
Although MGAP-1 and MAGP-2 are described as paralogs,
they support distinct functions in vivo that can explain
the lack of MFAP2 mutations in TAAD-affected subjects.16
In particular, Gibson et al.16 described distinct patterns
of tissue localization between MAGP-1 and MAGP-2 in
bovine: whereas MAGP-2 was not detected in the medial
layer of fetal thoracic aorta, in much of the peritubular ma-
trix of fetal and mature kidney, and in the mature ocular
zonule in contrast to MAGP-1, MAGP-2 was specifically
associated with fibrillin-containing microfibrils in nuchalJournal of Human Genetics 95, 736–743, December 4, 2014 739
Figure 3. Immunoblot Analysis of
MAGP-2 in Fibroblasts from Affected Indi-
viduals
Proteins were extracted from cellular
lysates (A) and extracellular media (B) of
fibroblasts from affected subjects car-
rying the nonsense (TAA-9801 family) or
missense (TAA-9178) mutations and
healthy control subjects. Intracellular solu-
ble proteins were extracted with TRIzol re-
agent (Life Technologies) according to the
manufacturer’s instructions. This method
avoids contamination by insoluble cell-
associated matrix such as matrix-associ-
ated MAGP-2. Extracellular proteins were
extracted from extracellular media after
centrifugation with the AMICON 10 kDa
filtration columns (Millipore). Immuno-
blots were realized via two antibodies
recognizing either N- or C-terminal do-
mains of MAGP-2 as mutations affect
N-terminal (p.Trp21Leu) or C-terminal
(p.Arg158*) domains or horseradish perox-
idase-conjugated b-tubulin (1:5,000 dilu-
tion, ab21058 from Abcam). Purified re-
combinant human MAGP-2 expressed in
HEK cells (TP303242 from Origene Technologies) was used as control on each blot. Densitometric analysis was performed with Scion
Image software (Scion Corporation). Immunoblots showed the presence in cellular lysates of both WT and truncated MAGP-2 in indi-
viduals heterozygous for the nonsense c.472C>T variant. (C) Quantification of immunoblots (N-term) showed that the band corre-
sponding to WT MAGP-2 represents less than 50% of the total MAGP-2 signal detected (normalized with b-tubulin; means5 standard
error of the mean). The band corresponding to the truncated protein was not found in extracellular medium.ligament, dermis, adventitia of aorta, glomerular mesan-
gium, and perimysium. Interestingly, homozygous Mfap5
knockoutmice display only hematopoietic features charac-and IBs were performed as described in Figure 3. WT MAGP-2 was de
p.Arg158* truncated MAGP-2 protein was detectable in cellular lysate
(C and D) Cellular lysates (C) and extracellular media (D) of transfe
analyzed. Immunoblots and checking of transfection efficacy were re
part of MAGP-2 was not performed because the mutation affects an a
(E) Quantification of immunoblots confirmed a significant decrease
pressed as means5 standard error of themean. Statistical differences
t test. The absence of p.Arg158* MAGP-2 precluded statistical analysi
significant at values of p < 0.05. Data shown for each construct were
740 The American Journal of Human Genetics 95, 736–743, Decembterized by neutropenia.23 However, an age-dependant
aortic dilation is observed in double-knockout Mfap5/
and Mfap2/ mice. Because all TAAD-affected individualsFigure 4. Immunoblot Analysis of WT,
p.Arg158*, and p.Trp21Leu MAGP-2 in
Transfected HEK
(A and B) Cellular lysates (A) and extracel-
lular media (B) of transfected HEK with WT
or c.472C>T (p.Arg158*) coding vectors
were analyzed. Transient transfection assays
of constructs were performed in HEK293 H
cells (HEK, GIBCO Life Technologies)
because they do not express endogenous
MFAP5. Cells were transiently cotransfected
in serum-free DMEM (GIBCO Life Technol-
ogies) with 1 mg of a vector encoding WT
or mutated c.472C>T (p.Arg158*) MAGP-2
and 1 mg of an empty vector (pcDNA3.1).
The Fugene 6 transfection agent was used
(Promega). After transfection, HEK cells
were incubated for 24 hr. The extracellular
medium was harvested and cells were
washed three times with PBS prior to RNA/
protein extractions. Transfection efficiency
was checked and showed proper expression
of theMFAP5 transcripts forWTandmutant
constructs (Figure S1). Protein extraction
tected in both cellular lysates and extracellular media as expected.
s and totally absent from the extracellular medium.
cted HEK with WT or c.62G>T (p.Trp21Leu) coding vectors were
alized as previously described. Immunoblotting of the N-terminal
mino acid located in the epitope.
of intracellular presence of p.Trp21Leu MAGP-2. All values are ex-
betweenWTand p.Trp21LeuMAGP-2were analyzed by a Student’s
s of WT versus p.Arg158*. Differences were considered statistically
pooled from three independent transfection assays.
er 4, 2014
Figure 5. Immunohistology of Aortic Wall from a Dissection Case in Family TAA-9178
Aneurysmal ascending aorta was collected during aortic surgery for the proband from the TAA-9178 family (Bichat University Hospital)
(II:2, heterozygous for the c.62G>TMFAP5mutation). Normal thoracic aorta was obtained from a normal organ transplant donor with
the authorization of the French Biomedicine Agency. Aneurysmal tissue was sampled in the outer curvature, the most dilated part of the
ascending aorta. Aortic specimens were fixed in Bouin’s solution, and serial sections (6 mm thickness) were obtained from each specimen.
(A) Masson’s trichrome and Alcian blue revealed a disorganization of the tunica media with a loss of smooth muscle cells (SMCs) and
proteoglycan accumulation, respectively, compared to healthy aorta.
(B) Immunohistofluorescent staining for the same subject and control samples was performed with antibodies to nuclear phosphory-
lated SMAD2/3 (phosphorylated Ser 423/425 SMAD2/3, sc-11769 from Santa Cruz Biotechnology) and mouse monoclonal antibody
to TGF-b1 (sc-65378 from Santa Cruz Biotechnology). Alexa Fluor 555-conjugated secondary antibodies tomouse and rabbit (Invitrogen,
Life Technologies) were used. Because pathology samples had been fixed in Bouin’s solution, SMC nuclei could not be Dapi-stained.
Elastic fibers appear in green (TGF-b1) and yellow (p-SMAD2/3). Staining showed enhanced TGF-b signaling in patient compared to
healthy aorta.were systematically screened for mutations both inMFAP2
and MFAP5, the existence in human of a digenism as that
seen in mouse can be excluded.
Here we report that mutations in MFAP5 cause familial
forms of thoracic aneurysms. Aortic dilations observed in
both TAA-9801 and TAA-9178 families affect the aortic
root, similar to what has been observed previously with
mutations in TAAD-associated genes. The occurrence of
other phenotypic features (i.e., other MFS, LDS, or AOS fea-
tures) was quite infrequent in these two families, suggest-
ing that loss of function of MFAP5 leads to nonsyndromic
TAAD. Interestingly and in addition to aortic dilation,
familial history of lone paroxysmal atrial fibrillation
(PAF) was reported in the TAA-9801 family. The proband
was indeed diagnosed during an exploration for lone
PAF. This unusual presentation of aortic aneurysms might
explain why only two TAAD-affected families with MFAP5
mutations were detected after screening of individuals in
the French and Texan populations.
MFAP5 encodes a structural component of the ECM
localized in fibrillin-containing microfibrils, either elastin
associated or elastin free.16 Multiple experimental findings
showed that MAGP-2 plays an important role in the
physiology of the ECM through interactions with different
microfibrillar components such as fibrillin-1, fibrillin-2, fi-
bulin-1, and tropoelastine.16,24,25 More recently it has been
shown that mouse MAGP-2 can bind reversibly different
TGF-b/BMP superfamily members such as TGF-b1, TGF-
b2, and BMP2 possibly through an acidic region in the NThe Americanterminus of the protein.23 It must be noted that mutations
in genes encoding several partners of MAGP-2, in partic-
ular FBN1 and TGFB2, are associated with thoracic aortic
aneurysm.8,26 These data confirm a close link between
MAGP-2 and pathways involved in pathogenesis of
TAAD. Thus, as in FBN1 mutations, loss of function of
MFAP5 might affect the structural function of the vessel
by directly altering ECM organization and/or deposition
of elastic fibers leading to fibers disruption and to dilation
of the aorta.
In conclusion, we describeMFAP5mutations involved in
the physiopathology of TAAD. In this disease attention
had shifted away from the matrix due to the identification
of mutations in genes involved in TGF-b signaling and
SMC contraction. Our results highlight the interest of
identifying TAAD mutations in genes encoding other
structural proteins of the ECM.Supplemental Data
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